{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:16:52Z","timestamp":1789791412518,"version":"4.0.1"},"publisher-location":"Cham","reference-count":143,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030663056","type":"print"},{"value":"9783030663063","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/164_2020_351","type":"book-chapter","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T03:02:43Z","timestamp":1586401363000},"page":"63-89","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Novel Native and Engineered Botulinum Neurotoxins"],"prefix":"10.1007","author":[{"given":"Lance","family":"Steward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell F.","family":"Brin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Brideau-Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,10]]},"reference":[{"key":"351_CR1","first-page":"89","volume":"305","author":"A Albanese","year":"2011","unstructured":"Albanese A (2011) Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA Dermatol 305:89\u201390","journal-title":"JAMA Dermatol"},{"key":"351_CR2","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1023\/A:1026367917639","volume":"16","author":"BS Antharavally","year":"1997","unstructured":"Antharavally BS, DasGupta BR (1997) Covalent structure of botulinum neurotoxin type E: location of sulfhydryl groups, and disulfide bridges and identification of C-termini of light and heavy chains. J Protein Chem 16:787\u2013799","journal-title":"J Protein Chem"},{"key":"351_CR3","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/j.1471-4159.2004.02844.x","volume":"91","author":"S Bade","year":"2004","unstructured":"Bade S, Rummel A, Reisinger C, Karnath T, Ahnert-Hilger G, Bigalke H et al (2004) Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates. J Neurochem 91:1461\u20131472","journal-title":"J Neurochem"},{"key":"351_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.pep.2009.12.013","volume":"71","author":"PA Band","year":"2010","unstructured":"Band PA, Blais S, Neubert TA, Cardozo TJ, Ichtchenko K (2010) Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery. Protein Expr Purif 71:62\u201373","journal-title":"Protein Expr Purif"},{"key":"351_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/infdis\/jit449","volume":"209","author":"JR Barash","year":"2014","unstructured":"Barash JR, Arnon SS (2014) A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis 209:183\u2013191","journal-title":"J Infect Dis"},{"key":"351_CR6","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.toxicon.2018.11.025","volume":"156 Suppl 1","author":"M Beard","year":"2018","unstructured":"Beard M, Burgin D, Hornby F, Donald S, Krupp J, Dong M et al (2018) Recombinant expression and characterization of a botulinum neurotoxin serotype X chimera. Toxicon 156 Suppl 1:S8","journal-title":"Toxicon"},{"key":"351_CR7","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.toxicon.2018.11.030","volume":"156 Suppl 1","author":"T Binz","year":"2018","unstructured":"Binz T, Beard M, Sikorra S, Schwede S, Elliott M, Donald S et al (2018) Mutations in light chain of botulinum neurotoxin a enable cleavage of human SNAP-23. Toxicon 156 Suppl 1:S10","journal-title":"Toxicon"},{"key":"351_CR8","unstructured":"BOTOX Cosmetic\u00ae (onabotulinumtoxinA) [prescribing information] (2018) Irvine: Allergan Pharmaceuticals Ireland, a subsidiary of Allergan, Inc."},{"key":"351_CR9","unstructured":"BOTOX\u00ae (onabotulinumtoxinA) [prescribing information] (2019) Irvine: Allergan Pharmaceuticals Ireland, a subsidiary of Allergan, Inc."},{"key":"351_CR10","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1128\/AEM.01795-14","volume":"80","author":"M Bradshaw","year":"2014","unstructured":"Bradshaw M, Tepp WH, Whitemarsh RC, Pellett S, Johnson EA (2014) Holotoxin activity of botulinum neurotoxin subtype A4 originating from a nontoxigenic Clostridium botulinum expression system. Appl Environ Microbiol 80:7415\u20137422","journal-title":"Appl Environ Microbiol"},{"key":"351_CR11","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","volume":"53","author":"MF Brin","year":"1999","unstructured":"Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J et al (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A\u2013resistant cervical dystonia. Neurology 53:1431\u20131438","journal-title":"Neurology"},{"key":"351_CR12","first-page":"227","volume":"8","author":"MF Brin","year":"2014","unstructured":"Brin MF, James C, Maltman J (2014) Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics 8:227\u2013241","journal-title":"Biologics"},{"key":"351_CR13","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/1873-3468.12969","volume":"592","author":"J Brunt","year":"2018","unstructured":"Brunt J, Carter AT, Stringer SC, Peck MW (2018) Identification of a novel botulinum neurotoxin gene cluster in Enterococcus. FEBS Lett 592:310\u2013317","journal-title":"FEBS Lett"},{"issue":"Suppl 1","key":"351_CR14","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.toxicon.2018.11.036","volume":"156","author":"D Burgin","year":"2018","unstructured":"Burgin D, P\u00e9rier C, Elliot M, Hornby F, Mir I, Beard M (2018) New modified recombinant botulinum neurotoxin type F with enhanced potency. Toxicon 156(Suppl 1):S12\u2013SS3","journal-title":"Toxicon"},{"key":"351_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1128\/JB.4.5.555-570.1.1919","volume":"4","author":"GS Burke","year":"1919","unstructured":"Burke GS (1919) Notes on bacillus botulinus. J Bacteriol 4:555\u201370.1","journal-title":"J Bacteriol"},{"key":"351_CR16","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1097\/DSS.0000000000001206","volume":"43","author":"J Carruthers","year":"2017","unstructured":"Carruthers J, Solish N, Humphrey S, Rosen N, Muhn C, Bertucci V et al (2017) Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatol Surg 43:1321\u20131331","journal-title":"Dermatol Surg"},{"key":"351_CR17","first-page":"1454","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","unstructured":"Centers for Disease Control and Prevention (CDC) (2011) Notice of CDC\u2019s discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins. MMWR Morb Mortal Wkly Rep 60:1454\u20131455","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"351_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S1046-5928(02)00002-5","volume":"25","author":"JA Chaddock","year":"2002","unstructured":"Chaddock JA, Herbert MH, Ling RJ, Alexander FC, Fooks SJ, Revell DF et al (2002) Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A. Protein Expr Purif 25:219\u2013228","journal-title":"Protein Expr Purif"},{"key":"351_CR19","doi-asserted-by":"publisher","first-page":"9180","DOI":"10.1073\/pnas.0903111106","volume":"106","author":"S Chen","year":"2009","unstructured":"Chen S, Barbieri JT (2009) Engineering botulinum neurotoxin to extend therapeutic intervention. Proc Natl Acad Sci U S A 106:9180\u20139184","journal-title":"Proc Natl Acad Sci U S A"},{"key":"351_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/978-1-4614-9454-6_8","volume-title":"Molecular aspects of botulinum neurotoxin \u2013 current topics in neurotoxicity","author":"S Chen","year":"2014","unstructured":"Chen S, Barbieri JT (2014) Protease activity of the botulinum neurotoxins. In: Foster KA (ed) Molecular aspects of botulinum neurotoxin \u2013 current topics in neurotoxicity, vol 4. Springer, New York, pp 171\u2013189"},{"key":"351_CR21","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","volume":"65","author":"CL Comella","year":"2005","unstructured":"Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S et al (2005) Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 65:1423\u20131429","journal-title":"Neurology"},{"key":"351_CR22","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1038\/s41467-019-10732-w","volume":"10","author":"E Contreras","year":"2019","unstructured":"Contreras E, Masuyer G, Qureshi N, Chawla S, Dhillon HS, Lee HL et al (2019) A neurotoxin that specifically targets Anopheles mosquitoes. Nat Commun 10:2869","journal-title":"Nat Commun"},{"key":"351_CR23","doi-asserted-by":"publisher","first-page":"18197","DOI":"10.1073\/pnas.1007125107","volume":"107","author":"F Darios","year":"2010","unstructured":"Darios F, Niranjan D, Ferrari E, Zhang F, Soloviev M, Rummel A et al (2010) SNARE tagging allows stepwise assembly of a multimodular medicinal toxin. Proc Natl Acad Sci U S A 107:18197\u201318201","journal-title":"Proc Natl Acad Sci U S A"},{"key":"351_CR25","doi-asserted-by":"crossref","first-page":"20838","DOI":"10.1016\/S0021-9258(19)36861-9","volume":"268","author":"A de Paiva","year":"1993","unstructured":"de Paiva A, Poulain B, Lawrence GW, Shone CC, Tauc L, Dolly JO (1993) A role for the interchain disulfide or its participating thiols in the internalization of botulinum neurotoxin A revealed by a toxin derivative that binds to ecto-acceptors and inhibits transmitter release intracellularly. J Biol Chem 268:20838\u201320844","journal-title":"J Biol Chem"},{"key":"351_CR26","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1128\/JB.172.5.2498-2503.1990","volume":"172","author":"ML Dekleva","year":"1990","unstructured":"Dekleva ML, Dasgupta BR (1990) Purification and characterization of a protease from clostridium botulinum type A that nicks single-chain type A botulinum neurotoxin into the di-chain form. J Bacteriol 172:2498\u20132503","journal-title":"J Bacteriol"},{"key":"351_CR27","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/B978-0-12-800188-2.00034-3","volume-title":"The comprehensive sourcebook of bacterial protein toxins","author":"O Dolly","year":"2015","unstructured":"Dolly O, Wang J (2015) Engineering of botulinum neurotoxins as novel therapeutic tools. In: Alouf J, Ladant D, Popoff MR (eds) The comprehensive sourcebook of bacterial protein toxins, 4th edn. Elsevier Ltd., Amsterdam, pp 995\u20131015","edition":"4"},{"key":"351_CR28","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/infdis\/jit450","volume":"209","author":"N Dover","year":"2014","unstructured":"Dover N, Barash JR, Hill KK, Xie G, Arnon SS (2014) Molecular characterization of a novel botulinum neurotoxin type H gene. J Infect Dis 209:192\u2013202","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"351_CR29","first-page":"S26","volume":"156","author":"D Dressler","year":"2018","unstructured":"Dressler D, Truong D, Comella C, Jankovic J, Brashear A, Patel A et al (2018) Immunogenicity of daxibotulinumtoxinA for injection in adults with cervical dystonia from a phase 2 dose-escalation multicenter study. Toxicon 156(Suppl 1):S26\u2013SS7","journal-title":"Toxicon"},{"key":"351_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1128\/JB.72.4.455-460.1956","volume":"72","author":"JT Duff","year":"1956","unstructured":"Duff JT, Wright GG, Yarinsky A (1956) Activation of Clostridium botulinum type E toxin by trypsin. J Bacteriol 72:455\u2013460","journal-title":"J Bacteriol"},{"key":"351_CR31","unstructured":"DYSPORT\u00ae (abobotulinumtoxinA) [prescribing information] (2018) Basking Ridge: Ipsen Biopharmaceuticals, Inc."},{"key":"351_CR32","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1111\/j.1742-4658.2012.08638.x","volume":"279","author":"OP Edupuganti","year":"2012","unstructured":"Edupuganti OP, Ovsepian SV, Wang J, Zurawski TH, Schmidt JJ, Smith L et al (2012) Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin. FEBS J 279:2555\u20132567","journal-title":"FEBS J"},{"key":"351_CR33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1128\/AM.24.1.108-113.1972","volume":"24","author":"MW Eklund","year":"1972","unstructured":"Eklund MW, Poysky FT (1972) Activation of a toxic component of Clostridium botulinum types C and D by trypsin. Appl Microbiol 24:108\u2013113","journal-title":"Appl Microbiol"},{"key":"351_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0304-3940(97)13448-6","volume":"224","author":"R Eleopra","year":"1997","unstructured":"Eleopra R, Tugnoli V, Rossetto O, Montecucco C, De Grandis D (1997) Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci Lett 224:91\u201394","journal-title":"Neurosci Lett"},{"key":"351_CR35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0304-3940(98)00775-7","volume":"256","author":"R Eleopra","year":"1998","unstructured":"Eleopra R, Tugnoli V, Rossetto O, De Grandis D, Montecucco C (1998) Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256:135\u2013138","journal-title":"Neurosci Lett"},{"key":"351_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/BF03033930","volume":"9","author":"R Eleopra","year":"2006","unstructured":"Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C, Dressler D (2006) Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F. Neurotox Res 9:127\u2013131","journal-title":"Neurotox Res"},{"key":"351_CR37","doi-asserted-by":"publisher","first-page":"e0185628","DOI":"10.1371\/journal.pone.0185628","volume":"12","author":"M Elliott","year":"2017","unstructured":"Elliott M, Maignel J, Liu SM, Favre-Guilmard C, Mir I, Farrow P et al (2017) Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems. PLoS One 12:e0185628","journal-title":"PLoS One"},{"key":"351_CR38","doi-asserted-by":"publisher","first-page":"eaau7196","DOI":"10.1126\/sciadv.aau7196","volume":"5","author":"M Elliott","year":"2019","unstructured":"Elliott M, Favre-Guilmard C, Liu SM, Maignel J, Masuyer G, Beard M et al (2019) Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models. Sci Adv 5:eaau7196","journal-title":"Sci Adv"},{"key":"351_CR39","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00702-007-0728-2","volume":"115","author":"FJ Erbguth","year":"2008","unstructured":"Erbguth FJ (2008) From poison to remedy: the chequered history of botulinum toxin. J Neural Transm 115:559\u2013565","journal-title":"J Neural Transm"},{"key":"351_CR40","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/toxins3040345","volume":"3","author":"E Ferrari","year":"2011","unstructured":"Ferrari E, Maywood ES, Restani L, Caleo M, Pirazzini M, Rossetto O et al (2011) Re-assembled botulinum neurotoxin inhibits CNS functions without systemic toxicity. Toxins 3:345\u2013355","journal-title":"Toxins"},{"key":"351_CR41","doi-asserted-by":"publisher","first-page":"29604","DOI":"10.1074\/jbc.M703619200","volume":"282","author":"A Fischer","year":"2007","unstructured":"Fischer A, Montal M (2007) Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J Biol Chem 282:29604\u201329611","journal-title":"J Biol Chem"},{"key":"351_CR42","first-page":"S35","volume":"156 Suppl 1","author":"K Foster","year":"2018","unstructured":"Foster K, Blum T, Beard M, Chaddock J, Kupinski A, Harding A et al (2018) Phage-assisted continuous evolution of botulinum neurotoxin light chains generates novel light chains with modified snare cleavage specificity. Toxicon 156 Suppl 1:S35","journal-title":"Toxicon"},{"key":"351_CR43","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/CCID.S160723","volume":"11","author":"J Frevert","year":"2018","unstructured":"Frevert J, Ahn KY, Park MY, Sunga O (2018) Comparison of botulinum neurotoxin type A formulations in Asia. Clin Cosmet Investig Dermatol 11:327\u2013331","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"351_CR44","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1128\/JB.89.5.1176-1179.1965","volume":"89","author":"J Gerwing","year":"1965","unstructured":"Gerwing J, Dolman CE, Ko A (1965) Mechanism of tryptic activation of Clostridium botulinum type E toxin. J Bacteriol 89:1176\u20131179","journal-title":"J Bacteriol"},{"key":"351_CR45","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1128\/MR.46.1.86-94.1982","volume":"46","author":"DM Gill","year":"1982","unstructured":"Gill DM (1982) Bacterial toxins: a table of lethal amounts. Microbiol Rev 46:86\u201394","journal-title":"Microbiol Rev"},{"key":"351_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.toxicon.2008.04.035","volume":"51 Suppl 1","author":"MA Gilmore","year":"2008","unstructured":"Gilmore MA, Sun S, Ordas JV, Arpawong HT, Okawa Y, Satorius A et al (2008) Fully active recombinant BoNT\/E purified from E. coli in high yield. Toxicon 51 Suppl 1:11\u201312","journal-title":"Toxicon"},{"key":"351_CR47","first-page":"221","volume":"215","author":"DF Gim\u00e9nez","year":"1970","unstructured":"Gim\u00e9nez DF, Ciccarelli AS (1970) Another type of Clostridium botulinum. Zentralbl Bakteriol Orig 215:221\u2013224","journal-title":"Zentralbl Bakteriol Orig"},{"key":"351_CR48","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1111\/j.1524-4725.2012.02582.x","volume":"38","author":"R Glogau","year":"2012","unstructured":"Glogau R, Kane M, Beddingfield F, Somogyi C, Lei X, Caulkins C et al (2012) OnabotulinumtoxinA: a meta-analysis of duration of effect in the treatment of glabellar lines. Dermatol Surg 38:1794\u20131803","journal-title":"Dermatol Surg"},{"key":"351_CR49","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/mds.870080411","volume":"8","author":"PE Greene","year":"1993","unstructured":"Greene PE, Fahn S (1993) Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord 8:479\u2013483","journal-title":"Mov Disord"},{"key":"351_CR50","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1126\/science.1214270","volume":"335","author":"S Gu","year":"2012","unstructured":"Gu S, Rumpel S, Zhou J, Strotmeier J, Bigalke H, Perry K et al (2012) Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 335:977\u2013981","journal-title":"Science"},{"key":"351_CR51","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.tibtech.2004.04.006","volume":"22","author":"C Gustafsson","year":"2004","unstructured":"Gustafsson C, Govindarajan S, Minshull J (2004) Codon bias and heterologous protein expression. Trends Biotechnol 22:346\u2013353","journal-title":"Trends Biotechnol"},{"key":"351_CR52","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1002\/1873-3468.12889","volume":"591","author":"R Gustafsson","year":"2017","unstructured":"Gustafsson R, Berntsson RP, Martinez-Carranza M, El Tekle G, Odegrip R, Johnson EA et al (2017) Crystal structures of OrfX2 and P47 from a Botulinum neurotoxin OrfX-type gene cluster. FEBS Lett 591:3781\u20133792","journal-title":"FEBS Lett"},{"key":"351_CR53","doi-asserted-by":"publisher","first-page":"E195","DOI":"10.3390\/toxins10050195","volume":"10","author":"G Hackett","year":"2018","unstructured":"Hackett G, Moore K, Burgin D, Hornby F, Gray B, Elliott M et al (2018) Purification and characterization of recombinant botulinum neurotoxin serotype FA, also known as serotype H. Toxins 10:E195","journal-title":"Toxins"},{"key":"351_CR54","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.toxicon.2013.06.010","volume":"75","author":"M H\u00f6ltje","year":"2013","unstructured":"H\u00f6ltje M, Schulze S, Strotmeier J, Mahrhold S, Richter K, Binz T et al (2013) Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons. Toxicon 75:108\u2013121","journal-title":"Toxicon"},{"key":"351_CR55","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s00438-014-0887-4","volume":"289","author":"K Hosomi","year":"2014","unstructured":"Hosomi K, Sakaguchi Y, Kohda T, Gotoh K, Motooka D, Nakamura S et al (2014) Complete nucleotide sequence of a plasmid containing the botulinum neurotoxin gene in Clostridium botulinum type B strain 111 isolated from an infant patient in Japan. Mol Gen Genomics 289:1267\u20131274","journal-title":"Mol Gen Genomics"},{"key":"351_CR56","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1212\/01.wnl.0000249308.66959.43","volume":"67","author":"J Jankovic","year":"2006","unstructured":"Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A et al (2006) Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 67:2233\u20132235","journal-title":"Neurology"},{"key":"351_CR57","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/mdc3.12613","volume":"5","author":"J Jankovic","year":"2018","unstructured":"Jankovic J, Truong D, Patel AT, Brashear A, Evatt M, Rubio RG et al (2018) Injectable daxibotulinumtoxinaA in cervical dystonia: a phase 2 dose-escalation multicenter study. Mov Disord Clin Pract 5:273\u2013282","journal-title":"Mov Disord Clin Pract"},{"key":"351_CR58","unstructured":"JEUVEAU (prabotulinumtoxinA-xvfs) [prescribing information] (2019) Santa Barbara: Evolus Inc."},{"key":"351_CR59","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.1442-200X.1996.tb03542.x","volume":"38","author":"H Kakinuma","year":"1996","unstructured":"Kakinuma H, Maruyama H, Takahashi H, Yamakawa K, Nakamura S (1996) The first case of type B infant botulism in Japan. Acta Paediatr Jpn 38:541\u2013543","journal-title":"Acta Paediatr Jpn"},{"key":"351_CR60","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1021\/ac504716v","volume":"87","author":"SR Kalb","year":"2015","unstructured":"Kalb SR, Baudys J, Raphael BH, Dykes JK, L\u00faquez C, Maslanka SE et al (2015) Functional characterization of botulinum neurotoxin serotype H as a hybrid of known serotypes F and A (BoNT F\/A). Anal Chem 87:3911\u20133917","journal-title":"Anal Chem"},{"key":"351_CR61","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0041-008X(85)90342-4","volume":"79","author":"JA Kauffman","year":"1985","unstructured":"Kauffman JA, Way JF Jr, Siegel LS, Sellin LC (1985) Comparison of the action of types A and F botulinum toxin at the rat neuromuscular junction. Toxicol Appl Pharmacol 79:211\u2013217","journal-title":"Toxicol Appl Pharmacol"},{"key":"351_CR62","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.toxicon.2018.11.140","volume":"156 Suppl 1","author":"JA Kaufman-Janette","year":"2018","unstructured":"Kaufman-Janette JA, Solish N, Liu Y, Rubio RG, Gallagher CJ (2018) Pooled results from 2 phase 3 pivotal studies of daxibotulinumtoxinA for the treatment of glabellar lines. Toxicon 156 Suppl 1:S59","journal-title":"Toxicon"},{"key":"351_CR63","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/nau.22934","volume":"36","author":"M Kennelly","year":"2017","unstructured":"Kennelly M, Dmochowski R, Schulte-Baukloh H, Ethans K, Del Popolo G, Moore C et al (2017) Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: final results of a long-term extension study. Neurourol Urodyn 36:368\u2013375","journal-title":"Neurourol Urodyn"},{"key":"351_CR64","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/PRS.0000000000001032","volume":"135","author":"JE Kim","year":"2015","unstructured":"Kim JE, Song EJ, Choi GS, Lew BL, Sim WY, Kang H (2015) The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plast Reconstr Surg 135:732\u2013741","journal-title":"Plast Reconstr Surg"},{"key":"351_CR65","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1128\/IAI.65.11.4586-4591.1997","volume":"65","author":"N Kiyatkin","year":"1997","unstructured":"Kiyatkin N, Maksymowych AB, Simpson LL (1997) Induction of an immune response by oral administration of recombinant botulinum toxin. Infect Immun 65:4586\u20134591","journal-title":"Infect Immun"},{"key":"351_CR66","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1574-6968.1985.tb00658.x","volume":"27","author":"S Kozaki","year":"1985","unstructured":"Kozaki S, Oga Y, Kamata Y, Sakaguchi G (1985) Activation of Clostridium botulinum type B and E derivative toxins with lysine-specific proteases. FEMS Microbiol Lett 27:149\u2013154","journal-title":"FEMS Microbiol Lett"},{"key":"351_CR67","doi-asserted-by":"publisher","first-page":"14316","DOI":"10.1021\/bi701564f","volume":"46","author":"RV Kukreja","year":"2007","unstructured":"Kukreja RV, Singh BR (2007) Comparative role of neurotoxin-associated proteins in the structural stability and endopeptidase activity of botulinum neurotoxin complex types A and E. Biochemistry 46:14316\u201314324","journal-title":"Biochemistry"},{"key":"351_CR68","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jmb.2008.12.027","volume":"386","author":"D Kumaran","year":"2009","unstructured":"Kumaran D, Eswaramoorthy S, Furey W, Navaza J, Sax M, Swaminathan S (2009) Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation. J Mol Biol 386:233\u2013245","journal-title":"J Mol Biol"},{"key":"351_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuro.2016.12.008","volume":"59","author":"A Kutschenko","year":"2017","unstructured":"Kutschenko A, Reinert MC, Krez N, Liebetanz D, Rummel A (2017) BoNT\/AB hybrid maintains similar duration of paresis as BoNT\/A wild-type in murine running wheel assay. Neurotoxicology 59:1\u20138","journal-title":"Neurotoxicology"},{"key":"351_CR70","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.clinph.2019.02.007","volume":"130","author":"A Kutschenko","year":"2019","unstructured":"Kutschenko A, Weisemann J, Kollewe K, Fiedler T, Alvermann S, Boselt S et al (2019) Botulinum neurotoxin serotype D \u2013 a potential treatment alternative for BoNT\/A and B non-responding patients. Clin Neurophysiol 130:1066\u20131073","journal-title":"Clin Neurophysiol"},{"key":"351_CR71","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/2338","volume":"5","author":"DB Lacy","year":"1998","unstructured":"Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5:898\u2013902","journal-title":"Nat Struct Biol"},{"key":"351_CR72","doi-asserted-by":"publisher","first-page":"e1003690","DOI":"10.1371\/journal.ppat.1003690","volume":"9","author":"K Lee","year":"2013","unstructured":"Lee K, Gu S, Jin L, Le TT, Cheng LW, Strotmeier J et al (2013) Structure of a bimodular botulinum neurotoxin complex provides insights into its oral toxicity. PLoS Pathog 9:e1003690","journal-title":"PLoS Pathog"},{"key":"351_CR73","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1126\/science.1253823","volume":"344","author":"K Lee","year":"2014","unstructured":"Lee K, Zhong X, Gu S, Kruel AM, Dorner MB, Perry K et al (2014) Molecular basis for disruption of E-cadherin adhesion by botulinum neurotoxin A complex. Science 344:1405\u20131410","journal-title":"Science"},{"key":"351_CR24","doi-asserted-by":"crossref","unstructured":"L\u00f3pez de la Paz M, Scheps D, Jurk M, Hofmann F, Frevert J (2018) Rational design of botulinum neurotoxin A1 mutants with improved oxidative stability. Toxicon 147:54\u201357","DOI":"10.1016\/j.toxicon.2017.10.011"},{"key":"351_CR74","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJM199201303260516","volume":"326","author":"CL Ludlow","year":"1992","unstructured":"Ludlow CL, Hallett M, Rhew K, Cole R, Shimizu T, Sakaguchi G et al (1992) Therapeutic use of type F botulinum toxin. N Engl J Med 326:349\u2013350","journal-title":"N Engl J Med"},{"key":"351_CR75","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1080\/14656566.2016.1199687","volume":"17","author":"F Maffezzoni","year":"2016","unstructured":"Maffezzoni F, Formenti AM, Mazziotti G, Frara S, Giustina A (2016a) Current and future medical treatments for patients with acromegaly. Expert Opin Pharmacother 17:1631\u20131642","journal-title":"Expert Opin Pharmacother"},{"key":"351_CR76","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ghir.2016.10.001","volume":"30-31","author":"F Maffezzoni","year":"2016","unstructured":"Maffezzoni F, Frara S, Doga M, Mazziotti G, Giustina A (2016b) New medical therapies of acromegaly. Growth Hormon IGF Res 30-31:58\u201363","journal-title":"Growth Hormon IGF Res"},{"key":"351_CR77","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1432-1033.1988.tb14423.x","volume":"177","author":"EA Maisey","year":"1988","unstructured":"Maisey EA, Wadsworth JD, Poulain B, Shone CC, Melling J, Gibbs P et al (1988) Involvement of the constituent chains of botulinum neurotoxins A and B in the blockade of neurotransmitter release. Eur J Biochem 177:683\u2013691","journal-title":"Eur J Biochem"},{"key":"351_CR78","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.toxicon.2018.11.174","volume":"156","author":"R Malmirchegini","year":"2018","unstructured":"Malmirchegini R, Too P, Oliyai C, Joshi A (2018) Revance\u2019s novel peptide excipient, RTP004, and its role in stabilizing daxibotulinumtoxinA (DAXI) against aggregation. Toxicon 156:S72\u2013S73","journal-title":"Toxicon"},{"key":"351_CR79","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.febslet.2014.12.018","volume":"589","author":"MJ Mansfield","year":"2015","unstructured":"Mansfield MJ, Adams JB, Doxey AC (2015) Botulinum neurotoxin homologs in non-Clostridium species. FEBS Lett 589:342\u2013348","journal-title":"FEBS Lett"},{"key":"351_CR80","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/s41598-018-37647-8","volume":"9","author":"MJ Mansfield","year":"2019","unstructured":"Mansfield MJ, Wentz TG, Zhang S, Lee EJ, Dong M, Sharma SK et al (2019) Bioinformatic discovery of a toxin family in Chryseobacterium piperi with sequence similarity to botulinum neurotoxins. Sci Rep 9:1634","journal-title":"Sci Rep"},{"key":"351_CR81","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/infdis\/jiv327","volume":"213","author":"SE Maslanka","year":"2016","unstructured":"Maslanka SE, L\u00faquez C, Dykes JK, Tepp WH, Pier CL, Pellett S et al (2016) A novel botulinum neurotoxin, previously reported as serotype H, has a hybrid-like structure with regions of similarity to the structures of serotypes A and F and is neutralized with serotype A antitoxin. J Infect Dis 213:379\u2013385","journal-title":"J Infect Dis"},{"key":"351_CR82","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jsb.2010.11.010","volume":"174","author":"G Masuyer","year":"2011","unstructured":"Masuyer G, Beard M, Cadd VA, Chaddock JA, Ravi AK (2011) Structure and activity of a functional derivative of Clostridium botulinum neurotoxin B. J Struct Biol 174:52\u201357","journal-title":"J Struct Biol"},{"key":"351_CR83","doi-asserted-by":"publisher","first-page":"13397","DOI":"10.1038\/srep13397","volume":"5","author":"G Masuyer","year":"2015","unstructured":"Masuyer G, Davies JR, Moore K, Chaddock JA, Ravi AK (2015) Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors. Sci Rep 5:13397","journal-title":"Sci Rep"},{"key":"351_CR84","doi-asserted-by":"publisher","first-page":"4518","DOI":"10.1038\/s41598-018-22842-4","volume":"8","author":"G Masuyer","year":"2018","unstructured":"Masuyer G, Zhang S, Barkho S, Shen Y, Henriksson L, Ko\u0161enina S et al (2018) Structural characterisation of the catalytic domain of botulinum neurotoxin X \u2013 high activity and unique substrate specificity. Sci Rep 8:4518","journal-title":"Sci Rep"},{"key":"351_CR85","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0167-4781(96)00006-1","volume":"1307","author":"K Moriishi","year":"1996","unstructured":"Moriishi K, Koura M, Abe N, Fujii N, Fujinaga Y, Inoue K et al (1996) Mosaic structures of neurotoxins produced from Clostridium botulinum types C and D organisms. Biochim Biophys Acta 1307:123\u2013126","journal-title":"Biochim Biophys Acta"},{"key":"351_CR86","unstructured":"MYOBLOC\u00ae (rimabotulinumtoxinB) [prescribing information] (2009) South San Francisco: Solstice Neurosciences, Inc"},{"key":"351_CR87","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1021\/acs.bioconjchem.7b00157","volume":"28","author":"M Nugent","year":"2017","unstructured":"Nugent M, Wang J, Lawrence G, Zurawski T, Geoghegan JA, Dolly JO (2017) Conjugate of an IgG binding domain with botulinum neurotoxin A lacking the acceptor moiety targets its snare protease into TrkA-expressing cells when coupled to anti-TrkA IgG or Fc-betaNGF. Bioconjug Chem 28:1684\u20131692","journal-title":"Bioconjug Chem"},{"key":"351_CR88","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuropharm.2018.06.016","volume":"138","author":"M Nugent","year":"2018","unstructured":"Nugent M, Yusef YR, Meng J, Wang J, Dolly JO (2018) A SNAP-25 cleaving chimera of botulinum neurotoxin \/A and \/E prevents TNF\u03b1-induced elevation of the activities of native TRP channels on early postnatal rat dorsal root ganglion neurons. Neuropharmacology 138:257\u2013266","journal-title":"Neuropharmacology"},{"key":"351_CR89","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1128\/IAI.17.2.402-407.1977","volume":"17","author":"I Ohishi","year":"1977","unstructured":"Ohishi I, Sakaguchi G (1977) Activation of botulinum toxins in the absence of nicking. Infect Immun 17:402\u2013407","journal-title":"Infect Immun"},{"key":"351_CR90","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.bbrc.2011.01.093","volume":"405","author":"S Pellett","year":"2011","unstructured":"Pellett S, Tepp WH, Stanker LH, Band PA, Johnson EA, Ichtchenko K (2011) Neuronal targeting, internalization, and biological activity of a recombinant atoxic derivative of botulinum neurotoxin A. Biochem Biophys Res Commun 405:673\u2013677","journal-title":"Biochem Biophys Res Commun"},{"key":"351_CR91","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.toxicon.2015.04.015","volume":"101","author":"S Pellett","year":"2015","unstructured":"Pellett S, Tepp WH, Scherf JM, Pier CL, Johnson EA (2015) Activity of botulinum neurotoxin type D (strain 1873) in human neurons. Toxicon 101:63\u201369","journal-title":"Toxicon"},{"key":"351_CR92","doi-asserted-by":"publisher","first-page":"e00100","DOI":"10.1128\/mSphere.00100-15","volume":"1","author":"S Pellett","year":"2016","unstructured":"Pellett S, Tepp WH, Bradshaw M, Kalb SR, Dykes JK, Lin G et al (2016) Purification and characterization of botulinum neurotoxin FA from a genetically modified Clostridium botulinum strain. mSphere 1:e00100\u2013e00115","journal-title":"mSphere"},{"key":"351_CR93","doi-asserted-by":"publisher","first-page":"e00089","DOI":"10.1128\/mBio.00089-18","volume":"9","author":"S Pellett","year":"2018","unstructured":"Pellett S, Bradshaw M, Tepp WH, Pier CL, Whitemarsh RCM, Chen C et al (2018a) The light chain defines the duration of action of botulinum toxin serotype A subtypes. MBio 9:e00089\u2013e00018","journal-title":"MBio"},{"key":"351_CR94","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.toxicon.2017.12.048","volume":"147","author":"S Pellett","year":"2018","unstructured":"Pellett S, Tepp WH, Lin G, Johnson EA (2018b) Substrate cleavage and duration of action of botulinum neurotoxin type FA (\u201cH, HA\u201d). Toxicon 147:38\u201346","journal-title":"Toxicon"},{"key":"351_CR95","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1128\/IAI.00843-07","volume":"76","author":"CL Pier","year":"2008","unstructured":"Pier CL, Tepp WH, Bradshaw M, Johnson EA, Barbieri JT, Baldwin MR (2008) Recombinant holotoxoid vaccine against botulism. Infect Immun 76:437\u2013442","journal-title":"Infect Immun"},{"key":"351_CR96","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1111\/j.1462-5822.2011.01654.x","volume":"13","author":"M Pirazzini","year":"2011","unstructured":"Pirazzini M, Rossetto O, Bolognese P, Shone CC, Montecucco C (2011) Double anchorage to the membrane and intact inter-chain disulfide bond are required for the low pH induced entry of tetanus and botulinum neurotoxins into neurons. Cell Microbiol 13:1731\u20131743","journal-title":"Cell Microbiol"},{"key":"351_CR97","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1016\/j.febslet.2013.10.010","volume":"587","author":"M Pirazzini","year":"2013","unstructured":"Pirazzini M, Henke T, Rossetto O, Mahrhold S, Krez N, Rummel A et al (2013) Neutralisation of specific surface carboxylates speeds up translocation of botulinum neurotoxin type B enzymatic domain. FEBS Lett 587:3831\u20133836","journal-title":"FEBS Lett"},{"key":"351_CR98","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1124\/pr.116.012658","volume":"69","author":"M Pirazzini","year":"2017","unstructured":"Pirazzini M, Rossetto O, Eleopra R, Montecucco C (2017) Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev 69:200\u2013235","journal-title":"Pharmacol Rev"},{"key":"351_CR99","doi-asserted-by":"crossref","unstructured":"Pons L, Vilain C, Picaut P (2018) Outcomes of the first-in-human study with a recombinant botulinum toxin type E (rBoNT-E): safety and pharmacodynamic profile of rBoNT-E compared with abobotulinumtoxinA (Dysport\u00ae). Toxicon. 156(Suppl 1):S93","DOI":"10.1016\/j.toxicon.2018.11.224"},{"key":"351_CR100","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.vaccine.2017.12.064","volume":"36","author":"A Przedpelski","year":"2018","unstructured":"Przedpelski A, Tepp WH, Zuverink M, Johnson EA, Pellet S, Barbieri JT (2018) Enhancing toxin-based vaccines against botulism. Vaccine 36:827\u2013832","journal-title":"Vaccine"},{"key":"351_CR101","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s11095-015-1816-x","volume":"33","author":"E Ravichandran","year":"2016","unstructured":"Ravichandran E, Janardhanan P, Patel K, Riding S, Cai S, Singh BR (2016) In vivo toxicity and immunological characterization of detoxified recombinant botulinum neurotoxin type A. Pharm Res 33:639\u2013652","journal-title":"Pharm Res"},{"key":"351_CR102","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.toxicon.2015.09.009","volume":"107","author":"A Rummel","year":"2015","unstructured":"Rummel A (2015) The long journey of botulinum neurotoxins into the synapse. Toxicon 107:9\u201324","journal-title":"Toxicon"},{"key":"351_CR103","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1007\/s00253-015-7240-7","volume":"100","author":"P Saffarian","year":"2016","unstructured":"Saffarian P, Peerayeh SN, Amani J, Ebrahimi F, Sedighian H, Halabian R et al (2016a) TAT-BoNT\/A(1-448), a novel fusion protein as a therapeutic agent: analysis of transcutaneous delivery and enzyme activity. Appl Microbiol Biotechnol 100:2785\u20132795","journal-title":"Appl Microbiol Biotechnol"},{"key":"351_CR104","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1080\/21655979.2016.1201252","volume":"7","author":"P Saffarian","year":"2016","unstructured":"Saffarian P, Peerayeh SN, Amani J, Ebrahimi F, Sedighianrad H, Halabian R et al (2016b) Expression and purification of recombinant TAT-BoNT\/A(1-448) under denaturing and native conditions. Bioengineered 7:478\u2013483","journal-title":"Bioengineered"},{"key":"351_CR105","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.resmic.2014.07.016","volume":"166","author":"Y Sakaguchi","year":"2015","unstructured":"Sakaguchi Y, Suzuki T, Yamamoto Y, Nishikawa A, Oguma K (2015) Genomics of Clostridium botulinum group III strains. Res Microbiol 166:318\u2013325","journal-title":"Res Microbiol"},{"key":"351_CR106","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.toxicon.2017.09.006","volume":"139","author":"D Scheps","year":"2017","unstructured":"Scheps D, de la L\u00f3pez Paz M, Jurk M, Hofmann F, Frevert J (2017) Design of modified botulinum neurotoxin A1 variants with a shorter persistence of paralysis and duration of action. Toxicon 139:101\u2013108","journal-title":"Toxicon"},{"key":"351_CR107","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1128\/IAI.58.12.4136-4141.1990","volume":"58","author":"G Schiavo","year":"1990","unstructured":"Schiavo G, Papini E, Genna G, Montecucco C (1990) An intact interchain disulfide bond is required for the neurotoxicity of tetanus toxin. Infect Immun 58:4136\u20134141","journal-title":"Infect Immun"},{"key":"351_CR108","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jmb.2015.10.024","volume":"428","author":"S Sikorra","year":"2016","unstructured":"Sikorra S, Litschko C, M\u00fcller C, Thiel N, Galli T, Eichner T et al (2016) Identification and characterization of botulinum neurotoxin A substrate binding pockets and their re-engineering for human SNAP-23. J Mol Biol 428:372\u2013384","journal-title":"J Mol Biol"},{"key":"351_CR109","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1124\/jpet.103.058149","volume":"308","author":"LL Simpson","year":"2004","unstructured":"Simpson LL, Maksymowych AB, Park JB, Bora RS (2004) The role of the interchain disulfide bond in governing the pharmacological actions of botulinum toxin. J Pharmacol Exp Ther 308:857\u2013864","journal-title":"J Pharmacol Exp Ther"},{"key":"351_CR110","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.49.1.189","volume":"49","author":"RR Sloop","year":"1997","unstructured":"Sloop RR, Cole BA, Escutin RO (1997) Human response to botulinum toxin injection: type B compared with type A. Neurology 49:189\u2013194","journal-title":"Neurology"},{"key":"351_CR111","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/978-1-4614-9454-6_10","volume-title":"Molecular aspects of botulinum neurotoxin","author":"TJ Smith","year":"2014","unstructured":"Smith TJ (2014) Clostridium botulinum genomes and genetic diversity. In: Foster KA (ed) Molecular aspects of botulinum neurotoxin. Springer, New York, pp 207\u2013228"},{"key":"351_CR112","doi-asserted-by":"publisher","first-page":"e1271","DOI":"10.1371\/journal.pone.0001271","volume":"2","author":"TJ Smith","year":"2007","unstructured":"Smith TJ, Hill KK, Foley BT, Detter JC, Munk AC, Bruce DC et al (2007) Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT\/A3, \/Ba4 and \/B1 clusters are located within plasmids. PLoS One 2:e1271","journal-title":"PLoS One"},{"key":"351_CR113","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1172\/JCI63232","volume":"122","author":"E Somm","year":"2012","unstructured":"Somm E, Bonnet N, Martinez A, Marks PM, Cadd VA, Elliott M et al (2012) A botulinum toxin-derived targeted secretion inhibitor downregulates the GH\/IGF1 axis. J Clin Invest 122:3295\u20133306","journal-title":"J Clin Invest"},{"key":"351_CR114","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1210\/en.2013-1427","volume":"154","author":"E Somm","year":"2013","unstructured":"Somm E, Bonnet N, Zizzari P, Tolle V, Toulotte A, Jones R et al (2013) Comparative inhibition of the GH\/IGF-I axis obtained with either the targeted secretion inhibitor SXN101959 or the somatostatin analog octreotide in growing male rats. Endocrinology 154:4237\u20134248","journal-title":"Endocrinology"},{"key":"351_CR115","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1099\/ijs.0.027805-0","volume":"61","author":"BL Strahan","year":"2011","unstructured":"Strahan BL, Failor KC, Batties AM, Hayes PS, Cicconi KM, Mason CT et al (2011) Chryseobacterium piperi sp. nov., isolated from a freshwater creek. Int J Syst Evol Microbiol 61:2162\u20132166","journal-title":"Int J Syst Evol Microbiol"},{"key":"351_CR116","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1083\/jcb.200910119","volume":"189","author":"Y Sugawara","year":"2010","unstructured":"Sugawara Y, Matsumura T, Takegahara Y, Jin Y, Tsukasaki Y, Takeichi M et al (2010) Botulinum hemagglutinin disrupts the intercellular epithelial barrier by directly binding E-cadherin. J Cell Biol 189:691\u2013700","journal-title":"J Cell Biol"},{"key":"351_CR117","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/78005","volume":"7","author":"S Swaminathan","year":"2000","unstructured":"Swaminathan S, Eswaramoorthy S (2000) Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol 7:693\u2013699","journal-title":"Nat Struct Biol"},{"key":"351_CR118","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1637\/7347-022305R1.1","volume":"49","author":"M Takeda","year":"2005","unstructured":"Takeda M, Tsukamoto K, Kohda T, Matsui M, Mukamoto M, Kozaki S (2005) Characterization of the neurotoxin produced by isolates associated with avian botulism. Avian Dis 49:376\u2013381","journal-title":"Avian Dis"},{"key":"351_CR119","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41467-017-00064-y","volume":"8","author":"L Tao","year":"2017","unstructured":"Tao L, Peng L, Berntsson RP, Liu SM, Park S, Yu F et al (2017) Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors. Nat Commun 8:53","journal-title":"Nat Commun"},{"key":"351_CR120","doi-asserted-by":"publisher","first-page":"E190","DOI":"10.3390\/toxins10050190","volume":"10","author":"DA Tehran","year":"2018","unstructured":"Tehran DA, Pirazzini M (2018) Novel botulinum neurotoxins: exploring underneath the iceberg tip. Toxins 10:E190","journal-title":"Toxins"},{"key":"351_CR121","doi-asserted-by":"publisher","first-page":"30429","DOI":"10.1038\/srep30429","volume":"6","author":"E Vazquez-Cintron","year":"2016","unstructured":"Vazquez-Cintron E, Tenezaca L, Angeles C, Syngkon A, Liublinska V, Ichtchenko K et al (2016) Pre-clinical study of a novel recombinant botulinum neurotoxin derivative engineered for improved safety. Sci Rep 6:30429","journal-title":"Sci Rep"},{"key":"351_CR122","doi-asserted-by":"publisher","first-page":"e85517","DOI":"10.1371\/journal.pone.0085517","volume":"9","author":"EJ Vazquez-Cintron","year":"2014","unstructured":"Vazquez-Cintron EJ, Vakulenko M, Band PA, Stanker LH, Johnson EA, Ichtchenko K (2014) Atoxic derivative of botulinum neurotoxin A as a prototype molecular vehicle for targeted delivery to the neuronal cytoplasm. PLoS One 9:e85517","journal-title":"PLoS One"},{"key":"351_CR123","doi-asserted-by":"publisher","first-page":"42923","DOI":"10.1038\/srep42923","volume":"7","author":"EJ Vazquez-Cintron","year":"2017","unstructured":"Vazquez-Cintron EJ, Beske PH, Tenezaca L, Tran BQ, Oyler JM, Glotfelty EJ et al (2017) Engineering botulinum neurotoxin C1 as a molecular vehicle for intra-neuronal drug delivery. Sci Rep 7:42923","journal-title":"Sci Rep"},{"key":"351_CR124","doi-asserted-by":"publisher","first-page":"16993","DOI":"10.1074\/jbc.M710442200","volume":"283","author":"J Wang","year":"2008","unstructured":"Wang J, Meng J, Lawrence GW, Zurawski TH, Sasse A, Bodeker MO et al (2008) Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics. J Biol Chem 283:16993\u201317002","journal-title":"J Biol Chem"},{"key":"351_CR125","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1042\/BJ20120100","volume":"444","author":"J Wang","year":"2012","unstructured":"Wang J, Zurawski TH, Bodeker MO, Meng J, Boddul S, Aoki KR et al (2012a) Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B. Biochem J 444:59\u201367","journal-title":"Biochem J"},{"key":"351_CR126","doi-asserted-by":"publisher","first-page":"5035","DOI":"10.1096\/fj.12-210112","volume":"26","author":"J Wang","year":"2012","unstructured":"Wang J, Zurawski TH, Meng J, Lawrence GW, Aoki KR, Wheeler L et al (2012b) Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis. FASEB J 26:5035\u20135048","journal-title":"FASEB J"},{"key":"351_CR127","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.neuropharm.2017.03.026","volume":"118","author":"J Wang","year":"2017","unstructured":"Wang J, Casals-Diaz L, Zurawski T, Meng J, Moriarty O, Nealon J et al (2017) A novel therapeutic with two SNAP-25 inactivating proteases shows long-lasting anti-hyperalgesic activity in a rat model of neuropathic pain. Neuropharmacology 118:223\u2013232","journal-title":"Neuropharmacology"},{"key":"351_CR128","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3390\/toxins10060231","volume":"10","author":"RP Webb","year":"2018","unstructured":"Webb RP (2018) Engineering of botulinum neurotoxins for biomedical applications. Toxins 10:231","journal-title":"Toxins"},{"key":"351_CR129","doi-asserted-by":"publisher","first-page":"4490","DOI":"10.1016\/j.vaccine.2009.05.030","volume":"27","author":"RP Webb","year":"2009","unstructured":"Webb RP, Smith TJ, Wright P, Brown J, Smith LA (2009) Production of catalytically inactive BoNT\/A1 holoprotein and comparison with BoNT\/A1 subunit vaccines against toxin subtypes A1, A2, and A3. Vaccine 27:4490\u20134497","journal-title":"Vaccine"},{"key":"351_CR130","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3390\/toxins9090269","volume":"9","author":"RP Webb","year":"2017","unstructured":"Webb RP, Smith TJ, Smith LA, Wright PM, Guernieri RL, Brown JL et al (2017) Recombinant botulinum neurotoxin Hc subunit (BoNT Hc) and catalytically inactive Clostridium botulinum holoproteins (ciBoNT HPs) as vaccine candidates for the prevention of botulism. Toxins 9:269","journal-title":"Toxins"},{"key":"351_CR131","doi-asserted-by":"publisher","first-page":"5035","DOI":"10.3390\/toxins7124861","volume":"7","author":"J Weisemann","year":"2015","unstructured":"Weisemann J, Krez N, Fiebig U, Worbs S, Skiba M, Endermann T et al (2015) Generation and characterization of six recombinant botulinum neurotoxins as reference material to serve in an international proficiency test. Toxins 7:5035\u20135054","journal-title":"Toxins"},{"key":"351_CR132","doi-asserted-by":"publisher","first-page":"e01296","DOI":"10.1128\/genomeA.01296-17","volume":"5","author":"TG Wentz","year":"2017","unstructured":"Wentz TG, Muruvanda T, Lomonaco S, Thirunavukkarasu N, Hoffmann M, Allard MW et al (2017) Closed genome sequence of Chryseobacterium piperi strain CTMT\/ATCC BAA-1782, a gram-negative bacterium with clostridial neurotoxin-like coding sequences. Genome Announc 5:e01296\u2013e01217","journal-title":"Genome Announc"},{"key":"351_CR133","doi-asserted-by":"publisher","first-page":"e90252","DOI":"10.1371\/journal.pone.0090252","volume":"9","author":"RC Whitemarsh","year":"2014","unstructured":"Whitemarsh RC, Tepp WH, Johnson EA, Pellett S (2014) Persistence of botulinum neurotoxin A subtypes 1-5 in primary rat spinal cord cells. PLoS One 9:e90252","journal-title":"PLoS One"},{"key":"351_CR134","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.anaerobe.2017.12.009","volume":"49","author":"C Woudstra","year":"2018","unstructured":"Woudstra C, Le Mar\u00e9chal C, Souillard R, Anniballi F, Auricchio B, Bano L et al (2018) Investigation of Clostridium botulinum group III\u2019s mobilome content. Anaerobe 49:71\u201377","journal-title":"Anaerobe"},{"key":"351_CR135","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.toxicon.2018.11.280","volume":"156 Suppl 1","author":"L Wuchao","year":"2018","unstructured":"Wuchao L, Ya F, Junhui S, Zheng Z, Lizhen P, Libin Z et al (2018) An experimental study about neurotoxic potency of a novel botulinum toxin type A free of neurotoxin-associated proteins based on muscle strength measurement. Toxicon 156 Suppl 1:S117","journal-title":"Toxicon"},{"key":"351_CR136","unstructured":"XEOMIN\u00ae (incobotulinumtoxinA) [prescribing information] (2019) Raleigh: Merz Pharmaceuticals, LLC"},{"key":"351_CR137","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/j.toxicon.2018.11.282","volume":"156 Suppl 1","author":"N Yang","year":"2018","unstructured":"Yang N, Liu SM, Marlin S, Lewandowska A, Heyang M, Voisin T et al (2018) Chimeras of anthrax toxin and botulinum neurotoxin as novel analgesic proteins. Toxicon 156 Suppl 1:S118","journal-title":"Toxicon"},{"key":"351_CR138","doi-asserted-by":"publisher","first-page":"847e","DOI":"10.1097\/PRS.0000000000005029","volume":"142","author":"SG Yoelin","year":"2018","unstructured":"Yoelin SG, Dhawan SS, Vitarella D, Ahmad W, Hasan F, Abushakra S (2018) Safety and efficacy of EB-001, a novel type E botulinum toxin, in subjects with glabellar frown lines: results of a phase 2, randomized, placebo-controlled, ascending-dose study. Plast Reconstr Surg 142:847e\u2013855e","journal-title":"Plast Reconstr Surg"},{"key":"351_CR139","doi-asserted-by":"publisher","first-page":"e1006567","DOI":"10.1371\/journal.ppat.1006567","volume":"13","author":"G Zanetti","year":"2017","unstructured":"Zanetti G, Sikorra S, Rummel A, Krez N, Duregotti E, Negro S et al (2017) Botulinum neurotoxin C mutants reveal different effects of syntaxin or SNAP-25 proteolysis on neuromuscular transmission. PLoS Pathog 13:e1006567","journal-title":"PLoS Pathog"},{"key":"351_CR140","doi-asserted-by":"publisher","first-page":"14130","DOI":"10.1038\/ncomms14130","volume":"8","author":"S Zhang","year":"2017","unstructured":"Zhang S, Masuyer G, Zhang J, Shen Y, Lundin D, Henriksson L et al (2017) Identification and characterization of a novel botulinum neurotoxin. Nat Commun 8:14130","journal-title":"Nat Commun"},{"key":"351_CR141","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.chom.2017.12.018","volume":"23","author":"S Zhang","year":"2018","unstructured":"Zhang S, Lebreton F, Mansfield MJ, Miyashita SI, Zhang J, Schwartzman JA et al (2018) Identification of a botulinum neurotoxin-like toxin in a commensal strain of Enterococcus faecium. Cell Host Microbe 23:169\u2013176.e6","journal-title":"Cell Host Microbe"},{"key":"351_CR142","doi-asserted-by":"publisher","first-page":"15175","DOI":"10.1021\/bi00046a025","volume":"34","author":"L Zhou","year":"1995","unstructured":"Zhou L, de Paiva A, Liu D, Aoki R, Dolly JO (1995) Expression and purification of the light chain of botulinum neurotoxin A: a single mutation abolishes its cleavage of SNAP-25 and neurotoxicity after reconstitution with the heavy chain. Biochemistry 34:15175\u201315181","journal-title":"Biochemistry"},{"key":"351_CR143","doi-asserted-by":"publisher","first-page":"30257","DOI":"10.1038\/srep30257","volume":"6","author":"I Zornetta","year":"2016","unstructured":"Zornetta I, Azarnia Tehran D, Arrigoni G, Anniballi F, Bano L, Leka O et al (2016) The first non Clostridial botulinum-like toxin cleaves VAMP within the juxtamembrane domain. Sci Rep 6:30257","journal-title":"Sci Rep"}],"container-title":["Handbook of Experimental Pharmacology","Botulinum Toxin Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2020_351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T19:30:07Z","timestamp":1615145407000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/164_2020_351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030663056","9783030663063"],"references-count":143,"URL":"https:\/\/doi.org\/10.1007\/164_2020_351","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"10 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}